Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGFPU2)

• Drug Name: Linezolid Drug Info
• Synonyms: Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017
• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 441401
  ChEBI ID: CHEMBL126
  CAS Number: CAS 165800-03-3
  TTD Drug ID: D07UYO
  VARIDT Drug ID: DR00748
  ACDINA Drug ID: D00367

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome	2.01	7.25e-3	113/158 (71.52%)	RPS4Y1;RPL26L1;RPL36;...
DNA replication	1.94	1.09e-2	34/36 (94.44%)	MCM6;POLE2;RFC4;...
Pyrimidine metabolism	1.93	9.66e-3	40/56 (71.43%)	RRM2;DCK;DUT;...
Oxidative phosphorylation	1.87	1.27e-2	93/133 (69.92%)	ATP5F1E;ATP5MG;NDUFC1;...
Cell cycle	1.75	4.93e-2	110/124 (88.71%)	E2F2;CCNB1;PTTG1;...
AMPK signaling pathway	-1.61	4.77e-2	106/120 (88.33%)	IRS1;PPP2R5A;INSR;...
Inflammatory bowel disease	-1.61	4.84e-2	58/65 (89.23%)	GATA3;IL4R;IL21;...
Glycerophospholipid metabolism	-1.62	4.46e-2	71/98 (72.45%)	CEPT1;ETNPPL;PCYT2;...
PPAR signaling pathway	-1.64	3.82e-2	66/74 (89.19%)	SLC27A6;NR1H3;PCK2;...
Neutrophil extracellular trap formation	-1.66	2.97e-2	101/189 (53.44%)	C3;HDAC7;PLCG1;...
Glycerolipid metabolism	-1.67	3.04e-2	44/61 (72.13%)	AGPAT4;PNPLA2;DGKA;...
Complement and coagulation cascades	-1.69	2.15e-2	76/85 (89.41%)	C3AR1;TFPI;ITGAX;...
Graft-versus-host disease	-1.70	2.02e-2	32/42 (76.19%)	FASLG;HLA-DRA;KLRD1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.75	1.41e-2	79/89 (88.76%)	PLCG1;PPP3CA;MAP2K1;...
Vitamin digestion and absorption	-1.76	1.47e-2	17/24 (70.83%)	SLC5A6;APOB;SLC19A2;...
Ovarian steroidogenesis	-1.78	1.22e-2	41/51 (80.39%)	ADCY8;IGF1;HSD3B1;...
T cell receptor signaling pathway	-1.78	1.29e-2	93/104 (89.42%)	MALT1;IL5;RASGRP1;...
Allograft rejection	-1.80	1.15e-2	32/38 (84.21%)	FASLG;HLA-DRA;HLA-DRB1;...
Hematopoietic cell lineage	-1.82	1.14e-2	90/99 (90.91%)	IL1R2;IL5;HLA-DQB1;...
Mitophagy	-1.84	1.05e-2	56/68 (82.35%)	FIS1;BCL2L13;MFN2;...
Systemic lupus erythematosus	-1.84	8.59e-3	45/135 (33.33%)	HLA-DRA;HLA-DRB1;ACTN4;...
Autoimmune thyroid disease	-1.87	5.52e-3	46/53 (86.79%)	TG;FASLG;TSHR;...
Fat digestion and absorption	-1.89	3.97e-3	35/43 (81.4%)	SCARB1;AGPAT2;APOA1;...
Metabolism of xenobiotics by cytochrome P450	-1.90	4.30e-3	49/77 (63.64%)	GSTM5;ADH1B;SULT2A1;...
Steroid hormone biosynthesis	-1.92	2.34e-3	43/61 (70.49%)	CYP3A4;HSD17B6;CYP1A2;...
Asthma	-1.94	1.29e-3	25/31 (80.65%)	MS4A2;CD40LG;IL5;...
Ether lipid metabolism	-1.95	0.00e+0	32/49 (65.31%)	GDPD3;PLD3;PLA2G4C;...
alpha-Linolenic acid metabolism	-1.96	0.00e+0	17/25 (68%)	PLA2G4C;PLA2G4A;FADS2;...
Primary immunodeficiency	-2.00	0.00e+0	33/38 (86.84%)	TNFRSF13B;CD4;ZAP70;...
Retinol metabolism	-2.01	0.00e+0	41/68 (60.29%)	CYP2C8;CYP2A6;CYP3A4;...
Th1 and Th2 cell differentiation	-2.04	0.00e+0	80/92 (86.96%)	PLCG1;MAPK8;PPP3CA;...
Staphylococcus aureus infection	-2.09	0.00e+0	72/95 (75.79%)	C3AR1;KRT38;KRT33B;...
Linoleic acid metabolism	-2.11	0.00e+0	21/29 (72.41%)	CYP2C19;PLA2G4C;PLA2G4A;...
Cholesterol metabolism	-2.16	0.00e+0	44/50 (88%)	LRPAP1;SCARB1;APOA1;...
Arachidonic acid metabolism	-2.19	0.00e+0	48/61 (78.69%)	PTGES2;GGT5;EPHX2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H	Show ▼
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼
NL20	CVCL_0461	Homo sapiens	10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HFL1	CVCL_4295	Homo sapiens	10uM	24H	Show ▼
IMR-90	CVCL_0347	Homo sapiens	10uM	24H	Show ▼
WI-38	CVCL_0579	Homo sapiens	10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼